If you are a Plixorafenib clinical trial participant or candidate, you probably have questions about how the drug works. Here are the key facts.
Plixorafenib targets cancer cells with BRAF mutations
Plixorafenib is a small molecule that targets cancer cells with a mutated BRAF gene. Unlike conventional chemotherapy, this targeted therapy spares healthy cells, as their BRAF gene is not mutated.